Alunbrig 30 mg

Alunbrig 30 mg is an oral tablet containing brigatinib, used for targeted therapy. This medication is commonly prescribed for specific cancer treatments and is manufactured by Takeda Canada Inc.

Alunbrig 30 mg is primarily used in the treatment of certain types of cancer. Brigatinib, the active ingredient, is designed to target specific proteins involved in cancer cell growth. Patients often wonder, 'What is Alunbrig used for?' This medication is typically prescribed for advanced or metastatic cancers that have specific genetic markers.

Common effects of Alunbrig 30 mg may include nausea, fatigue, and cough. Some users experience changes in taste or vision. These effects can vary widely among individuals and are not exhaustive. Always consult a healthcare provider for personalized advice.

Alunbrig 30 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions. Pregnant women or those planning to become pregnant should discuss the risks with their healthcare provider.

Alunbrig 30 mg may interact with certain medications, including those that affect liver enzymes. Alcohol and other substances that impact liver function should be avoided unless approved by a healthcare provider. Always inform your healthcare provider about all medications you are taking.